Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema

Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema

Ilkka Laine,1–3 Juha-Matti Lindholm,1,2 Petteri Ylinen,1,4 Raimo Tuuminen1,2,5 1Helsinki Retina Research Group, University of Helsinki, Helsinki, 2Unit of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland; 3Department of Automation and Electrical Engineering, Aalto University, H...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Laine I, Lindholm JM, Ylinen P, Tuuminen R
Formato: article
Lenguaje:EN
Publicado: Dove Medical Press 2017
Materias:
Anti-VEGF
Bevacizumab
Cystoid macular edema
Dexamethasone implant
Retinal vein occlusion
Ophthalmology
RE1-994
Acceso en línea:https://doaj.org/article/c754cce0573240839c97848be96c510c
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
id oai:doaj.org-article:c754cce0573240839c97848be96c510c
record_format dspace
spelling oai:doaj.org-article:c754cce0573240839c97848be96c510c2021-12-02T02:00:22ZIntravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema1177-5483https://doaj.org/article/c754cce0573240839c97848be96c510c2017-11-01T00:00:00Zhttps://www.dovepress.com/intravitreal-bevacizumab-injections-versus-dexamethasone-implant-for-t-peer-reviewed-article-OPTHhttps://doaj.org/toc/1177-5483Ilkka Laine,1–3 Juha-Matti Lindholm,1,2 Petteri Ylinen,1,4 Raimo Tuuminen1,2,5 1Helsinki Retina Research Group, University of Helsinki, Helsinki, 2Unit of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland; 3Department of Automation and Electrical Engineering, Aalto University, Helsinki, Finland; 4Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland; 5The Insurance Centre, Patient Insurance Centre, Helsinki, Finland Purpose: To compare the short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal vein occlusion (CRVO).Design: A retrospective single-center study.Subjects: A total of 135 eyes of 135 patients with BRVO (n=83) and CRVO (n=52).Methods: Changes in clinical parameters were recorded before treatment and at the first and third month after commencement of IVB (n=121) and DEX (n=14).Main outcome measures: Central retinal thickness (CRT), intraocular pressure (IOP), and best-corrected visual acuity (BCVA).Results: The baseline parameters were comparable between IVB and DEX groups. After the first month, CRT decreased by 131.3±42.9 µm in IVB and by 266.9±48.3 µm in DEX (mean ± SEM; p=0.047). IOP change was –0.29±0.39 mmHg in IVB and +3.70±2.34 mmHg in DEX (p=0.005). IOP elevation to ≥25 mmHg and ≥5 mmHg from the baseline was observed in two of the DEX- and in none of the IVB-treated eyes (p=0.010). After the third month, no differences regarding CRT and IOP were observed between the treatment modalities. Moreover, BCVA gain was comparable between IVB (0.37±0.05 logarithm of minimum angle of resolution [logMAR] units) and DEX (0.33±0.30 logMAR units) groups.Conclusion: DEX was associated with faster resolution of CME, but had greater probability for short-term IOP elevation when compared to IVB. After the third month, treatments were comparably effective. Anatomical outcomes and adverse drug reactions of IVB versus DEX should be considered case specifically in patients having CME secondary to BRVO/CRVO. Keywords: anti-VEGF, bevacizumab, cystoid macular edema, dexamethasone implant, retinal vein occlusionLaine ILindholm JMYlinen PTuuminen RDove Medical PressarticleAnti-VEGFBevacizumabCystoid macular edemaDexamethasone implantRetinal vein occlusionOphthalmologyRE1-994ENClinical Ophthalmology, Vol Volume 11, Pp 2107-2112 (2017)
institution DOAJ
collection DOAJ
language EN
topic Anti-VEGF
Bevacizumab
Cystoid macular edema
Dexamethasone implant
Retinal vein occlusion
Ophthalmology
RE1-994
spellingShingle Anti-VEGF
Bevacizumab
Cystoid macular edema
Dexamethasone implant
Retinal vein occlusion
Ophthalmology
RE1-994
Laine I
Lindholm JM
Ylinen P
Tuuminen R
Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
description Ilkka Laine,1–3 Juha-Matti Lindholm,1,2 Petteri Ylinen,1,4 Raimo Tuuminen1,2,5 1Helsinki Retina Research Group, University of Helsinki, Helsinki, 2Unit of Ophthalmology, Kymenlaakso Central Hospital, Kotka, Finland; 3Department of Automation and Electrical Engineering, Aalto University, Helsinki, Finland; 4Department of Ophthalmology, Helsinki University Hospital, Helsinki, Finland; 5The Insurance Centre, Patient Insurance Centre, Helsinki, Finland Purpose: To compare the short-term effects of three monthly intravitreal bevacizumab (IVB) injections to single dexamethasone (DEX) implantation in treatment-naïve patients with cystoid macular edema (CME) secondary to branch (BRVO) and central retinal vein occlusion (CRVO).Design: A retrospective single-center study.Subjects: A total of 135 eyes of 135 patients with BRVO (n=83) and CRVO (n=52).Methods: Changes in clinical parameters were recorded before treatment and at the first and third month after commencement of IVB (n=121) and DEX (n=14).Main outcome measures: Central retinal thickness (CRT), intraocular pressure (IOP), and best-corrected visual acuity (BCVA).Results: The baseline parameters were comparable between IVB and DEX groups. After the first month, CRT decreased by 131.3±42.9 µm in IVB and by 266.9±48.3 µm in DEX (mean ± SEM; p=0.047). IOP change was –0.29±0.39 mmHg in IVB and +3.70±2.34 mmHg in DEX (p=0.005). IOP elevation to ≥25 mmHg and ≥5 mmHg from the baseline was observed in two of the DEX- and in none of the IVB-treated eyes (p=0.010). After the third month, no differences regarding CRT and IOP were observed between the treatment modalities. Moreover, BCVA gain was comparable between IVB (0.37±0.05 logarithm of minimum angle of resolution [logMAR] units) and DEX (0.33±0.30 logMAR units) groups.Conclusion: DEX was associated with faster resolution of CME, but had greater probability for short-term IOP elevation when compared to IVB. After the third month, treatments were comparably effective. Anatomical outcomes and adverse drug reactions of IVB versus DEX should be considered case specifically in patients having CME secondary to BRVO/CRVO. Keywords: anti-VEGF, bevacizumab, cystoid macular edema, dexamethasone implant, retinal vein occlusion
format article
author Laine I
Lindholm JM
Ylinen P
Tuuminen R
author_facet Laine I
Lindholm JM
Ylinen P
Tuuminen R
author_sort Laine I
title Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
title_short Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
title_full Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
title_fullStr Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
title_full_unstemmed Intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
title_sort intravitreal bevacizumab injections versus dexamethasone implant for treatment-naïve retinal vein occlusion related macular edema
publisher Dove Medical Press
publishDate 2017
url https://doaj.org/article/c754cce0573240839c97848be96c510c
work_keys_str_mv AT lainei intravitrealbevacizumabinjectionsversusdexamethasoneimplantfortreatmentnaiumlveretinalveinocclusionrelatedmacularedema
AT lindholmjm intravitrealbevacizumabinjectionsversusdexamethasoneimplantfortreatmentnaiumlveretinalveinocclusionrelatedmacularedema
AT ylinenp intravitrealbevacizumabinjectionsversusdexamethasoneimplantfortreatmentnaiumlveretinalveinocclusionrelatedmacularedema
AT tuuminenr intravitrealbevacizumabinjectionsversusdexamethasoneimplantfortreatmentnaiumlveretinalveinocclusionrelatedmacularedema
_version_ 1718402802110169088

Ejemplares similares